PACB: Pacific Biosciences of California, Inc. Stock

by  •  • Comments Off on PACB: Pacific Biosciences of California, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 468.43
Enterprise Value ($M) 1,284.82
Book Value ($M) 649.02
Book Value / Share 2.38
Price / Book 0.72
NCAV ($M) -343.88
NCAV / Share -1.26
Price / NCAV -1.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.19
Return on Assets (ROA) -0.16
Return on Equity (ROE) -0.43

Liquidity (mrq)
Quick Ratio 8.36
Current Ratio 9.28

Balance Sheet (mrq) ($M)
Current Assets 677.02
Assets 1,669.92
Liabilities 1,020.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 200.52
Operating Income -306.93
Net Income -306.74
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -259.17
Cash from Investing 4.60
Cash from Financing 108.89

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Madrone Capital Partners, Llc 7.90 5.90
02-12 13G/A Nikko Asset Management Americas, Inc. 4.93 -6.82
02-09 13G/A Jackson Square Partners, LLC 3.63 -35.32
02-05 13G/A Sumitomo Mitsui Trust Holdings, Inc. 4.93 -6.82
01-29 13G/A ARK Investment Management LLC 12.90 34.30
01-24 13G/A BlackRock Inc. 9.20 32.96
01-10 13G/A Vanguard Group Inc 10.02 32.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT P
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUA
2023-11-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPO
2023-08-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-10 1,662,993 3,515,162 47.31
2024-05-09 1,379,048 1,276,042 108.07
2024-05-08 1,844,489 1,940,937 95.03
2024-05-07 2,054,898 2,507,504 81.95
2024-05-06 3,090,068 4,712,307 65.57

(click for more detail)

Similar Companies
MLAB – Mesa Laboratories, Inc. NAUT – Nautilus Biotechnology, Inc.
NVMI – Nova Ltd. ROP – Roper Technologies, Inc.
RPID – Rapid Micro Biosystems, Inc.


Financial data and stock pages provided by
Fintel.io